<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Biglycan, an extracellular matrix protein, has been implicated in the <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development in various types of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical significance of biglycan in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, however, remains unclear </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, biglycan <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was analyzed in 110 samples (primary <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> and matched adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissue) derived from 55 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> using quantitative real-time RT-PCR </plain></SENT>
<SENT sid="3" pm="."><plain>The correlations between biglycan up-regulation and the clinicopathological data were also evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>We found that the up-regulation of biglycan occurred in 61.8% (34/55) of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues, and biglycan expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues was markedly higher than that in corresponding <z:mpath ids='MPATH_458'>normal</z:mpath> tissues (P = 0.0264) </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, statistical analysis displayed a significant correlation in biglycan up-regulation with poor <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation (P = 0.009), lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = 0.041), and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = 0.036) </plain></SENT>
<SENT sid="6" pm="."><plain>However, there was no significant correlation between biglycan up-regulation and other clinicopathological factors (<z:hpo ids='HP_0000001'>all</z:hpo> P &gt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, biglycan may be a potential marker for the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>